Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression
This study suggests that the DOX-PIO combination could be used in the clinic for osteosarcoma patients who develop DOX-resistance.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Actos | Bone Cancers | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Osteosarcoma | Study